While ASO-mediated knockdown of PrP holds promise as a potential disease-modifying therapy for prion disease, central nervous system (CNS)-targeting ASOs currently suffer from limited potency and biodistribution to deep brain regions6, the need for repeated intrathecal dosing and an unknown long-term tolerability profile. The gene discussed is PRNP; the disease is prion disease.